

3<sup>rd</sup> Edition

# Neuroscience Research

Focus: Emerging Fields in Neuroinflammation & Neurological Diseases

## Interleukin-33

### New Function of a Key Cytokine in Brain Development & Neurological Diseases


IL-33, a member of the IL-1 cytokine family, is constitutively expressed in fibroblasts, endothelial and epithelial cells exposed to the environment. IL-33 is a nuclear-associated cytokine that is normally released by damaged or necrotic cells acting as an “alarmin”, an immediate indicator of tissue stress.

IL-33 signals through ST2 coupled with the co-receptor IL-1 receptor accessory protein (IL-1RAcP). IL-33 is a potent inducer of type 2 immune responses in the contexts of parasite infections and allergic asthma. New studies have also extended the biology of IL-33 with other functions: i) to induce brown and beige adipocyte thermogenesis and to promote insulin secretion by pancreatic islets; ii) to facilitate Treg proliferation to suppress autoimmunity and potentiate neurological recovery; and iii) to have multiple roles in the brain.

IL-33 is abundantly expressed in specific regions of brain and spinal cord, mediates the interaction between immune, endothelial and CNS (central nervous system) resident cells and plays a key role in the development and homeostasis of the CNS. Astrocytes are the primary source of local IL-33 that stimulates synapse elimination by microglia during early CNS development (see FIGURE 1). Deletion of IL-33 in astrocytes leads to abnormal synaptic connections.

IL-33 is involved in the neuroinflammation of many neurological diseases such as Alzheimer’s disease (AD) and multiple sclerosis (MS).

Different studies suggest that IL-33 is involved in the myelination process during the CNS development and also likely the repair phase in demyelinating diseases such as MS and that IL-33 plays a critical role in the maintenance and repair of aging and stressed neurons during AD.



**FIGURE 1:** Astrocyte-derived IL-33 stimulates synapse elimination by microglia during CNS development.

#### SELECTED REVIEW ARTICLES

Astrocyte-derived interleukin-33 promotes microglial synapse engulfment and neural circuit development: I.D. Vainchtein, et al.; *Science* **359**, 1269 (2018) • Expression and Function of IL-33/ST2 Axis in the Central Nervous System Under Normal and Diseased Conditions: K. F Fairlie-Clarke, et al.; *Front. Immunol.* **9**, 2596 (2018) • IL33: Roles in Allergic Inflammation and Therapeutic Perspectives: B.C.L. Chan, et al.; *Front. Immunol.* **10**, 364 (2019)

#### CONTENTS

<b>Interleukin-33</b>	<b>1–2</b>
<b>Post-translational Modifications of Tubulins</b>	<b>3</b>
<b>Inflammasomes &amp; Neurodegeneration</b>	<b>4–5</b>
<b>Progranulin</b>	<b>6–7</b>
<b>PSD-95 – Synaptic Development &amp; Plasticity</b>	<b>7</b>
<b>Notch Signaling &amp; Microtubule Stabilization</b>	<b>8</b>
<b>Mitochondrial Dysfunction</b>	<b>9</b>
<b>Netrin-1 – Neuron Guidance Factor</b>	<b>10</b>
<b>Latest Insight: Irisin in Alzheimer's Disease</b>	<b>10</b>
<b>Dyes &amp; Stains</b>	<b>11</b>
<b>HDAC6 &amp; Alzheimer's Disease</b>	<b>11</b>
<b>Small Molecules for Neuroscience Research</b>	<b>12</b>


## Highly Active Human IL-33 Proteins

### IL-33 (oxidation resistant) (human) (rec.)

AG-40B-0160 **Untagged** 10 µg | 100 µg  
 AG-40B-0167 **His-tagged** 10 µg | 100 µg

**LIT:** Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation: E.S. Cohen, et al.; Nat. Commun. 6, ID8327 (2015)

**FIGURE:** Activation *in vivo* of Innate Lymphoid Cells 2 (ILC2) by IL-33 (oxidation resistant) (human) (rec.) (untagged) (AG-40B-0160). Method: C57BL/6 mice were injected daily for 3 days with PBS (Figure A) or IL-33 (oxidation resistant) (human) (rec.) (untagged) (AG-40B-0160) (at 0.4µg per mouse) (Figure B). At day 4, cells from bone marrows were stained and analyzed by flow cytometry. Levels of ST2 and KLRG1 on Innate Lymphoid Cells (gated as lineage negative, CD127 positive cells) are shown. Picture courtesy of Dr G.Verdeil / Dr S. Trabanelli (Camilla Jandus Group, Department of Fundamental Oncology, University of Lausanne).



## Other Recombinant IL-33 & Related Proteins

PROTEINS	PID
<b>IL-33 (human) (rec.) (untagged)</b>	AG-40B-0038
<b>IL-33 (human) (rec.) (His)</b>	AG-40A-0042
<b>IL-33 (mouse) (rec.) (untagged)</b>	AG-40B-0041
<b>IL-33 (mouse) (rec.) (His)</b>	AG-40A-0053

PROTEINS	PID
<b>ST2 (human):Fc (human) (rec.)</b>	AG-40A-0059
<b>IL-33R [ST2] (human):Fc (human) (rec.)</b>	CHI-HF-21033R
<b>IL-33R [ST2] (mouse):Fc (mouse) (rec.)</b>	CHI-MF-11033R

## IL-33 Blocking Antibody

### anti-IL-33 (mouse), mAb (rec.) (blocking) (Bondy-1-1)

AG-27B-0013 100 µg  
 AG-27B-0013PF Preservative Free 100 µg | 500 µg | 1mg

Inhibits binding of mouse IL-33 to ST2/IL-1RAcP.

**LIT:** Regulation of de novo adipocyte differentiation through crosstalk between adipocytes and pre-adipocytes: T.D. Challa, et al.; Diabetes 64, 4075 (2015) • Male-specific IL-33 expression regulates sex-dimorphic EAE susceptibility: A.E. Russi, et al; PNAS 115, E1520 (2018)


## ST2 Antibody for Flow Cytometry

### anti-ST2 (human), pAb

AG-25A-0058 100 µg  
 AG-25A-0058YTD ATTO 488 100 tests  
 AG-25A-0058YTS ATTO 647N 100 tests

**FIGURE:** Detection of endogenous human ST2 with anti-ST2 (human), pAb (AG-25A-0058).

**METHOD:** THP1 cells were stained with anti-ST2 (human), pAb (1:100 in PBS + 2% FCS) (Figure B) or with the secondary antibody alone (Figure A) for 1h at 4°C.



## Other IL-33 & Related Antibodies

ANTIBODIES	PID	SIZE	ISOTYPE/SOURCE	APPLICATION	SPECIES
<b>anti-IL-33, mAb (IL33026B)</b>	AG-20A-0043	50 µg   100 µg	Mouse IgG1κ	ELISA, IP, WB	Hu, Ms
<b>anti-IL-33 (human), mAb (IL33305B)</b>	AG-20A-0041	50 µg   100 µg	Mouse IgG2ak	FUNC, IHC, IP, WB	Hu
<b>anti-IL-33 (human), pAb</b>	AG-25A-0045	100 µg	Rabbit	ELISA, IHC, WB	Hu
<b>anti-IL-33 (mouse), pAb</b>	AG-25A-0047	100 µg	Rabbit	ELISA, WB	Ms
<b>anti-IL-33 (mouse), mAb (rec.) (Carly-1-4)</b>	AG-27B-0012	100 µg	Human IgG2λ	ELISA, WB	Ms
<b>anti-ST2 (human), mAb (ST33868)</b>	AG-20A-0044	50 µg   100 µg	Mouse IgG1κ	ELISA, IHC, WB	Hu

## HpARI – Suppressor of Type 2 (Allergic) Immune Response

### HpARI (Alarmin Release Inhibitor) (rec.) (His)

AG-40B-0178 50 µg | 3 x 50 µg

Specific for human and mouse.

During cell damage, HpARI gains access to the nucleus of necrotic cells, where it binds directly to IL-33 and nuclear DNA, preventing secretion and binding of IL-33 to its receptor.

**LIT:** M. Osbourne, et al.; Immunity 47, 739 (2017)

# The Tubulin Code: Post-translational Modifications of Tubulins

In neurons, microtubules, actin filaments and neurofilaments compose the cytoskeleton, maintaining cell polarity, architecture and morphology. Microtubules (MTs) are highly dynamic polymers formed of tubulin  $\alpha$  and  $\beta$  heterodimers. Regulation of MTs polymerization is controlled by microtubule associated proteins, post-translational modifications of tubulin  $\alpha$  and  $\beta$ , microtubules and signaling molecules. Deregulation of the neuronal cytoskeleton/MT function constitutes a key insult during the pathogenesis of nervous system diseases, including Amyotrophic Lateral Sclerosis, Alzheimer's diseases (AD), Hereditary Spastic Paraplegia, Parkinson's disease (PD) and others. **Post-translational modifications (PTMs)** are highly dynamic and often reversible processes where protein functional properties are altered by addition of a chemical group or another protein to its amino acid residues. Tubulins and microtubules (MTs) are major substrates for PTMs. They include tyrosination/detyrosination, D2-tubulin formation, **acetylation**, phosphorylation, polyamination, ubiquitination, **polyglutamylolation** and **glycylation** (see FIGURE 2). PTMs are involved in fine-tuning of interactions between microtubules and different MT-interacting proteins.




FIGURE 2: Tubulin PTM Overview. Adapted from C. Janke; *J. Cell. Biol.* 206, 461 (2014).

## UNIQUE

### Validated Post-translational Modification-specific Antibodies

ANTIBODIES	PID	SIZE	ISOTYPE/SOURCE	APPLICATION
<b>anti-<math>\alpha</math>-Tubulin (acetylated), mAb (TEU318)</b>	AG-20B-0068	100 $\mu$ g	Mouse IgG1	ICC, WB
<b>anti-Polyglutamylolation Modification, mAb (GT335)</b>	AG-20B-0020	100 $\mu$ g	Mouse IgG1 $\kappa$	EM, ICC, IHC, IP, WB
<b>anti-Polyglutamylolation Modification, mAb (GT335) (Biotin)</b>	AG-20B-0020B	100 $\mu$ g	Mouse IgG1 $\kappa$	ICC, IHC, IP, WB
<b>anti-Polyglutamate chain (polyE), pAb (IN105)</b>	AG-25B-0030	50 $\mu$ g	Rabbit	ICC, IHC, WB
<b>NEW anti-Tubulin (glycyated), pAb (Gly-pep1)</b>	AG-25B-0034	100 $\mu$ g	Rabbit	ICC, IP, WB

### Recombinant Microtubule-target Antibodies

ANTIBODIES	PID	SIZE	ISOTYPE/SOURCE	APPLICATION	SPECIES
<b>anti-Tubulin-GTP, mAb (rec.) (MB11) UNIQUE</b>	AG-27B-0009	100 $\mu$ g	Human IgG2 $\lambda$	ICC	Hu, Ms, Rt, Dr
<b>anti-<math>\alpha</math>-Tubulin, mAb (rec.) (F2C)</b>	AG-27B-0005	100 $\mu$ g	Human IgG2 $\lambda$	ICC, WB	Hu, Ms, Bv
<b>anti-<math>\alpha</math>-Tubulin, mAb (rec.) (F2C) (ATTO 488)</b>	AG-27B-0005TD	100 $\mu$ g	Human IgG2 $\lambda$	ICC	Hu, Ms, Bv
<b>anti-<math>\beta</math>-Tubulin, mAb (rec.) (S11B)</b>	AG-27B-0008	100 $\mu$ g	Human IgG2 $\lambda$	ELISA, ICC, WB	Hu, Ms, Rt, Pg, Dr, Mk


### Rab1-GTP and Rab6-GTP Specific Antibodies

Rab proteins, members of the small GTPase superfamily, are important regulators of vesicle transport via interactions with effector proteins and motor proteins. Rab1 and 6 are implicated in anterograde and retrograde trafficking in the secretory pathway. Rab1 has been shown to be involved in **autophagy** by helping the formation of the pre-autophagosomal isolation membrane (phagophore). Rab6 also functions as modulator of the unfolded protein response (UPR), helping the recovery from an ER stress insult. Rab6 is upregulated in Alzheimer's disease brain.

ANTIBODIES	PID	SIZE	ISOTYPE/SOURCE	APPLICATION	SPECIES
<b>anti-Rab1-GTP, mAb (rec.) (ROF7)</b>	AG-27B-0006	100 $\mu$ g	Human IgG2 $\lambda$	ICC, IP	Hu, Ms, Rt, Dg
<b>anti-Rab6-GTP, mAb (rec.) (AA2)</b>	AG-27B-0004	100 $\mu$ g	Human IgG2 $\lambda$	ICC	Hu, Ms, Dr
<b>anti-Rab6-GTP, mAb (rec.) (AA2) (ATTO 488)</b>	AG-27B-0004TD	100 $\mu$ g	Human IgG2 $\lambda$	ICC	Hu, Ms, Dr

# Inflammasomes & Neuroinflammation/Neurodegeneration

**Neuroinflammation** is an **innate immune response in the CNS** (central nervous system) against harmful and irritable stimuli such as pathogens, metabolic toxic waste or chronic mild stress that occurs in response to trauma, infections and/or neurodegenerative diseases. The main cell types contributing to the innate immune response are microglia, trafficking macrophages and astrocytes. These cells constantly survey the proximal environment through pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs), scavenger receptors (SRs) and **NOD-like receptors (NLRs)** (e.g. inflammasome complexes). These NLRs recognize not only exogenous pathogen-associated molecular patterns (PAMPs) but also endogenous modified molecules called damage-associated molecular patterns (DAMPs). After activation of the pattern recognition receptors and release of immune molecules (e.g. cytokines), the innate immune system launches inflammatory and regulatory responses in order to counteract infection, injury and maintenance of tissue homeostasis. Although the evolutionary function is neuroprotective, innate immune responses can also promote immunopathology when they are excessive (e.g. chronic neuroinflammation). During chronic activation, the sustained exposure of neurons to pro-inflammatory mediators can cause neuronal dysfunction and contribute to cell death. As chronic neuroinflammation is observed at relatively early stages of neurodegenerative diseases, targeting the mechanisms that drive this process may be useful for diagnostic and therapeutic purposes.



**FIGURE 3:** Selected activation factors, inflammasome complexes and target cells in the CNS.

Neuroinflammation is mediated in part by protein complexes known as **inflammasomes**. The inflammasomes can be activated in the CNS under diverse conditions that trigger inflammation, including acute infection (e.g. viruses, bacteria), chronic sterile inflammation (e.g. misfolded proteins such as amyloid- $\beta$ ,  $\alpha$ -synuclein and prion protein) and acute sterile injury (ATP excess) (see FIGURE 3). Inflammasome activation has been demonstrated in CNS-resident cell types including microglia, astrocytes and neurons. Assembly of inflammasomes (NLRP1/2/3 and NLRC4/IPAF) activates pro-inflammatory caspase-1, which then cleaves the precursor forms of pro-inflammatory cytokines IL-1 and IL-18 into their active forms, as well as the intracellular gasdermin D, which leads to a particular form of inflammatory cell death called pyroptosis. These pro-inflammatory effectors promote a variety of innate immune processes associated with infection, inflammation and autoimmunity, and play an instrumental role in the onset of neuroinflammation and subsequent occurrence of neurodegenerative diseases, cognitive impairment and dementia. NLRP1/2/3 and NLRC4/IPAF inflammasomes may also have a role in the etiologies of depression, Alzheimer's disease (AD) and in metabolic disorders, such as Type II diabetes, obesity and cardiovascular diseases that have been shown to be co-morbid with psychiatric illnesses.

**SELECTED REVIEWS:** Inflammasomes in the CNS: J.G. Walsh, et al.; Nat. Rev. Neurosci. 15, 84 (2014) • Innate immune activation in neurodegenerative disease: M.T. Heneka, et al.; Nat. Rev. Immunol. 14, 463 (2014) • Inflammation in neurodegenerative diseases-an update: S. Amor, et al.; Immunol. 142, 151 (2014) • Inflammasomes in neuroinflammatory and neurodegenerative diseases. S. Voet, et al.; EMBO Mol. Med. 11, e10248 (2019)

## NLRP3 Antibody

### anti-NLRP3/NALP3, mAb (Cryo-2)

AG-20B-0014


100  $\mu$ g

**Clone** Cryo-2  
**Isotype** Mouse IgG2b  
**Immunogen** Recombinant mouse NLRP3/NALP3 (pyrin domain/aa 1-93)  
**Application** ICC, IHC, IP, WB (1  $\mu$ g/ml) (see online protocol)  
**Specificity** Recognizes human and mouse NLRP3/NALP3.

**FIGURE:** Mouse NLRP3 is detected in mouse macrophages using the monoclonal antibody to NLRP3 (Cryo-2) (Prod. No. AG-20B-0014).

**METHOD:** Cell extracts from mouse macrophages (BMDMs) WT (+/+), NLRP3 +/- (lane 2) or NLRP3 -/- (lane 3) with or without treatment with LPS (50ng/ml) for 3h, were separated by SDS-PAGE under reducing conditions, transferred to nitrocellulose and incubated with the mAb to NLRP3 (Cryo-2) (1  $\mu$ g/ml). Proteins are visualized by a chemiluminescence detection system.

## THE STANDARD



THE STANDARDS FROM THE EXPERTS &amp; VALIDATED BY KEY LABORATORIES!


## Immunoblotting for Activated/Cleaved Caspase-1

### anti-Caspase-1 (p20) (mouse), mAb (Casper-1)

AG-20B-0042 100 µg  
AG-20B-0042B Biotin 100 µg

**Clone** Casper-1  
**Isotype** Mouse IgG1  
**Immunogen** Recombinant mouse caspase-1  
**Application** WB (1 µg/ml) (see online protocol), IHC (PS), IP  
**Specificity** Recognizes endogenous full-length and activated (p20 fragment) mouse caspase-1.

**FIGURE:** Mouse caspase-1 (p20) is detected by immunoblotting using anti-Caspase-1 (p20) (mouse), mAb (Casper-1) (Prod. No. AG-20B-0042).




**METHOD:** Caspase-1 was analyzed by Western blot in cell extracts and supernatants of differentiated bone marrow-derived dendritic cells (BMDCs) from wild-type, NLRP3<sup>-/-</sup> and caspase-1<sup>-/-</sup> mice activated or not by 5 µM Nigericin (Prod. No. AG-CN2-0020) for 30 min. Cell extracts and supernatants were separated by SDS-PAGE under reducing conditions, transferred to nitrocellulose and incubated with anti-Caspase-1 (p20) (mouse), mAb (Casper-1) (1 µg/ml). Proteins were visualized by a chemiluminescence detection system.

### anti-Caspase-1 (p20) (human), mAb (Bally-1)

AG-20B-0048 100 µg  
AG-20B-0048B Biotin 100 µg

**Clone** Bally-1  
**Isotype** Mouse IgG1  
**Immunogen** Recombinant human caspase-1  
**Application** WB (1 µg/ml) (see online protocol)  
**Specificity** Recognizes endogenous full-length and activated (p20 fragment) human caspase-1.

**FIGURE:** Human Caspase-1 (p20) is detected by immunoblotting using anti-Caspase-1 (p20) (human), mAb (Bally-1) (Prod. No. AG-20B-0048).



**METHOD:** Caspase-1 was analyzed by Western blot in supernatants of THP1 cells differentiated for 3h with 0.5 µM PMA (Prod. No. AG-CN2-0010) and activated (lane 2) or not (lane 1) by 5 µM Nigericin (Prod. No. AG-CN2-0020) for 1h. Supernatants (30 µl) were separated by SDS-PAGE under reducing conditions, transferred to nitrocellulose and incubated with anti-Caspase-1 (p20) (human), mAb (Bally-1) (1 µg/ml). Proteins were visualized by a chemiluminescence detection system.


## Standard Inflammasomes Signaling Antibodies

ANTIBODIES	PID	SIZE	SPECIFICITY
<b>anti-Asc, pAb (AL177)</b>	AG-25B-0006	100 µg	Recognizes human and mouse Asc.
<b>anti-Caspase-1 (p10) (mouse), mAb (Casper-2)</b>	AG-20B-0044	100 µg	Recognizes endogenous full-length and activated (p10 fragment) of mouse caspase-1.
<b>anti-Caspase-4 /11 (p20), mAb (Flamy-1)</b>	AG-20B-0060	100 µg	Recognizes endogenous full-length and activated (p20) fragment of mouse and human caspase-4/11.
<b>anti-IL-1α (p18) (mouse), mAb (Teo-1)</b>	AG-20B-0064	100 µg	Recognizes full-length and cleaved (p18) fragment of mouse IL-1α.
<b>anti-Caspase-8 (mouse), mAb (1G12)</b>	AG-20T-0137	100 µg	Recognizes full-length and cleaved (p18) fragment of mouse caspase-8.
<b>anti-Caspase-8 (human), mAb (C15)</b>	AG-20B-0057	50 µg   100 µg	Recognizes the p18 subunit of human caspase-8.
<b>anti-Gasdermin D (mouse), pAb (IN110)</b>	AG-25B-0036	100 µg	Recognizes full-length and cleaved C-terminus domain of mouse gasdermin D.

## Key NLRP3 Inflammasome Activators and Inhibitors

**BULK**

PRODUCT NAME	PID	SIZE	DESCRIPTION
<b>Monosodium urate (crystals)</b>	AG-CR1-3950	2 mg   2 x 2 mg	Potent NLRP3 inflammasome activator.
<b>Monosodium urate (ready-to-use)</b>	AG-CR1-3951	10 mg	Potent NLRP3 inflammasome activator.
<b>Nigericin . Na</b>	AG-CN2-0020	5 mg   25 mg	Potent NLRP3 inflammasome activator.
<b>MCC950 . Na (water soluble)</b>	AG-CR1-3615	1 mg   5 mg   10 mg	Potent and selective NLRP3 inflammasome inhibitor.




**For a comprehensive Overview on Unique Inflammasome Reagents ask for AdipoGen Life Sciences' Inflammasome Signaling Brochure & Wallchart!**

# Progranulin – Marker of Neuroinflammation

Progranulin (PGRN) is a cysteine-rich protein, composed of seven ~6kDa granulin (GRN) proteins, that shows multifunctional biological activities, including major roles in cancer, inflammation, metabolic disease and neurodegeneration, especially as a valuable biomarker for Frontotemporal Lobar Degeneration (FTLD). PGRN is an abundant, non-conventional, stress-induced, extracellular matrix-bound secreted growth factor-like molecule and cytoplasmic chaperone, that functions in a cellular and disease specific pattern. PGRN binds to several functionally different receptor families in a cell/tissue specific and condition/disease-dependent manner. For example, PGRN binding with TNFR and DR3 has an important anti-inflammatory role in immune cells, particularly Tregs and macrophages. PGRN/Ephrin type-A receptor 2 (EphA2) interaction is involved in the proliferative influence of PGRN. PGRN binds and activates Notch receptors, enhancing the regenerative capacity of injured neurons. PGRN is also a lysosomal resident protein and sortilin and lipoprotein receptor-related protein 1 (LRP1) have been demonstrated to be the lysosomal trafficking receptors for PGRN with the help of Prosaposin. In the brain, PGRN is primarily expressed in mature neurons and microglia. Absence of progranulin in microglia causes increased production and release of multiple cytokines, suggesting that PGRN regulates microglia activation. PGRN seems to affect microglial proliferation, recruitment, differentiation, activation and phagocytosis, suggesting that PGRN plays a central role in the regulation of neuroinflammatory responses. In neurons, PGRN i) co-localizes in late endosomes and early lysosomes with the transmembrane protein TMEM106B, ii) co-localizes with markers such as BDNF along axons, iii) influences synaptic structure and function at synaptic and extra-synaptic sites, where it is secreted in an activity-dependent manner, and iv) extracellular PGRN is endocytosed and delivered to lysosomes. The lysosomal function of PGRN is not well characterized, but probably involves regulation of proteins such as cathepsins, glucocerebrosidase (GBA) or TMEM106B and likely contributes to neurodegeneration (see FIGURE 4).

**SELECTED REVIEWS:** The lysosomal function of progranulin, a guardian against neurodegeneration: D.H. Paushter, et al.; Acta Neuropathol. 136, 1 (2018) • Progranulin: A conductor of receptors orchestra, a chaperone of lysosomal enzymes and a therapeutic target for multiple diseases: Y. Cui, et al.; Cytokine Growth Factor Rev. 45, 53 (2019)



**FIGURE 4:** The roles and binding partners of progranulin in neuronal cells.

## Standard Progranulin ELISA Kits

<b>Progranulin (human) ELISA Kit</b>	AG-45A-0018Y
<b>Progranulin (mouse) ELISA Kit</b>	AG-45A-0019Y
<b>Progranulin (rat) ELISA Kit</b>	AG-45A-0043Y



- **Trusted Reproducible Results!**
- **Used to Determine Cut-Off values for FTLD!**
- **Cited in Hundreds of Scientific Publications!**

## Tag-free Progranulins

**BULK**

### Progranulin (human) (rec.) (untagged)

AG-40A-0188Y 10 µg | 50 µg

### Progranulin (mouse) (rec.) (untagged)

AG-40A-0189Y 10 µg | 50 µg

### Progranulin (rat) (rec.) (untagged)

AG-40A-0196Y 10 µg | 50 µg

- Higher activity compared to tagged Progranulins
- Suitable for in vitro and in vivo studies
- Reflects the native sequence with no additional amino acids
- Affinity purified
- Low endotoxin levels (<0.01EU/µg)

## Progranulin Antibodies & Tagged Proteins

ANTIBODIES	PID	SIZE	ISOTYPE/SOURCE	APPLICATION	SPECIES
<b>anti-Progranulin (human), pAb</b>	AG-25A-0112	100 µg	Guinea pig	ELISA, IHC, WB	Hu
<b>anti-Progranulin (mouse), pAb</b>	AG-25A-0093	100 µg	Rat	ELISA, WB	Ms

PROTEINS	PID	SIZE	SOURCE	ENDOTOXIN	SPECIES
<b>Progranulin (human) (rec.)</b>	AG-40A-0068Y	10 µg   50 µg	HEK293 Cells	<0.01EU/µg	Hu
<b>Progranulin (rat) (rec.)</b>	AG-40A-0194	10 µg   50 µg	HEK293 Cells	<0.1EU/µg	Rt

## Related Products

ANTIBODIES	PID	SIZE	ISOTYPE/SOURCE	APPLICATION	SPECIES
<b>anti-Granulin C (human), pAb</b>	AG-25A-0090	100 µg	Rabbit	ELISA, WB	Hu

PROTEINS	PID	SIZE	SOURCE	ENDOTOXIN	SPECIES
<b>Granulin C (human) (rec.) (His)</b>	AG-40A-0129	10 µg   50 µg	E. coli	<1EU/µg	Hu

## PSD-95 – Key Protein in Synaptic Development & Plasticity

PSD-95 is a member of proteins located at a specialized postsynaptic membrane region, called the postsynaptic density (PSD). PSD-95 is the most abundant scaffold protein specifically enriched in the PSD. Through its PDZ domains, PSD-95 assembles various synaptic components at the PSD including intracellular signaling molecules (e.g. SynGAP and kalirin-7), ion channels (e.g. stargazin/AMPA receptors [AMPA] and NMDA receptors) and cell adhesion molecules (e.g. neuroligin). PSD-95 plays a primary role in synaptic development and maturation and is regulated by palmitoylation at its N-terminal cysteine residues leading to its postsynaptic targeting. Palmitoylated PSD-95 is almost exclusively localized at excitatory synapses in neurons.

**SELECTED REVIEWS:** Posttranslational Modifications Regulate the Postsynaptic Localization of PSD-95: D. Vallejo, et al.; Mol. Neurobiol. 54, 1759 (2017) • Role of Palmitoylation of Postsynaptic Proteins in Promoting Synaptic Plasticity: L. Matt, et al.; Front. Mol. Neurosci. 12, 8 (2019)

**UNIQUE**


### anti-PSD-95 (palmitoylated), mAb (rec.) (PF11)

AG-27B-0021

100 µg

**Clone** PF11  
**Isotype** Human IgG2  
**Immunogen** Palmitoylated PSD-95  
**Application** ICC, IHC  
**Specificity** Recognizes human, mouse and rat palmitoylated PSD-95.

**LIT:** Local palmitoylation cycles define activity-regulated postsynaptic subdomains: Y. Fukata, et al.; J. Cell Biol. 202, 145 (2013)



**FIGURE:** Palmitoylated PSD-95 is detected by immunocytochemistry using anti-PSD-95 (palmitoylated), mAb (rec.) (PF11) (Prod. No AG-27B-0021).

# Notch Signaling & Neurogenesis

Notch signaling plays critical roles in neural stem cell maintenance and neurogenesis. Notch functions depend on regulation and cross-talk with other regulatory mechanisms. Deregulation of Notch signaling is involved in many neurodegenerative diseases and brain disorders. ADAM17/TACE, an ectodomain shedding protease, is responsible for the processing of a diverse variety of membrane-anchored cytokines, including the extracellular Notch Receptor 1. It has roles in neurodegenerative diseases and in several physiological processes including proteolysis, adhesion, intracellular signaling, migration and proliferation. **ADAM17/TACE** plays a key role in **impairing neurogenesis in brain injuries**, thus becoming a new therapeutic target to promote endogenous neurogenesis to regenerate brain injuries.

**SELECTED REVIEWS:** Role of Notch Signaling Pathway in Glioblastoma Pathogenesis: R. Bazzoni, et al.; *Cancers* **11**, E292 (2019) • ADAM17/TACE: a key molecule in brain injury regeneration: S. Dominguez-Garcia, et al.; *Neural Regen. Res.* **14**, 1378 (2019)

## Potent ADAM17 Blocking Antibodies

**anti-ADAM17 (human), mAb (rec.) (blocking) (D1(A12)) (preservative free)**

AG-27B-6000PF 100 µg


**anti-ADAM17 (human), mAb (rec.) (blocking) (D1(A12)) (Fab Fragment) (His) (preservative free)**

AG-27B-6003PF 100 µg

Recognizes the catalytic and non-catalytic domain of human ADAM17 (TACE) through its variable light (VL) domain and variable heavy (VH) domain, respectively. Does not bind recombinant mouse ADAM17 ectodomain.

**Functional Application (Blocking):** Inhibits ADAM17 activity at 15µg/ml (200nM).

**LIT:** Cross-domain inhibition of TACE ectodomain: C.J. Tape, et al.; *PNAS* **108**, 5578 (2011)



**FIGURE:** D1(A12) IgG inhibits constitutive shedding of TNF-α from IGROV1 (human ovarian cancer cell line) into culture medium. Medium was collected after 48 hours of incubation with or without IgGs at 200nM.

Visit [www.adipogen.com](http://www.adipogen.com) for a Comprehensive Panel of Validated Notch Pathway Reagents!

## Microtubule Stabilization & Axonal Morphology

Several studies show that the morphology of the neuron can be influenced by **microtubule** and **actin filament cytoskeleton** dynamics, and that neurite outgrowth can be modulated with stabilizing and destabilizing agents. Activation of the **Notch signaling pathway** results in stabilization of microtubules leading to regulation of axonal morphology, with thicker neurites, fewer branches and loss of synaptic varicosity. This Notch-dependent stabilization of microtubules is likely due to increase in acetylation and polyglutamylation of α-tubulins, both of which are markers of stable microtubules.

**LIT:** Notch signalling in adult neurons: a potential target for microtubule stabilization: S.A. Bonini, et al.; *Ther. Adv. Neurol. Disord.* **6**, 375 (2013) • Microtubule-stabilizing agents as potential therapeutics for neurodegenerative disease: K.R. Brunden, et al.; *Bioorg. Med. Chem.* **22**, 5040 (2014)

### Small Molecule Cytoskeletal Modulators


<b>Dynasore</b>	Dynamin Inhibitor	AG-CR1-0045
<b>Jasplakinolide</b>	F-actin Stabilization	AG-CN2-0037
<b>Latrunculin A</b>	F-actin Depolymerization	AG-CN2-0027
<b>Latrunculin B</b>	F-actin Depolymerization	AG-CN2-0031
<b>Swinholide A</b>	F-actin Inhibitor	AG-CN2-0035
<b>Cytochalasin B</b>	Actin Depolymerization	AG-CN2-0504
<b>Cucurbitacin E</b>	Actin Depolymerization	AG-CN2-0474
<b>Colchicine</b>	Microtubule Inhibitor	AG-CN2-0048
<b>Colcemid</b>	Microtubule Inhibitor	AG-CR1-3567
<b>Ilimaquinone</b>	Microtubule Inhibitor	AG-CN2-0038
<b>Nocodazole</b>	Microtubule Inhibitor	AG-CR1-0019
<b>Paclitaxel</b>	Microtubule Stabilizer	AG-CN2-0045
<b>Phomopsin A</b>	Microtubule Inhibitor	AG-CN2-0515
<b>Podophyllotoxin</b>	Microtubule Inhibitor	AG-CN2-0049
<b>Pseudolaric acid B</b>	Microtubule Inhibitor	AG-CN2-0083



## Mitochondria and Neurodegenerative Diseases

Mitochondria are organelles responsible for orchestrating cellular energy production pathways, including the metabolic tricarboxylic acid (TCA) cycle to generate metabolites and ATP. They are highly dynamic organelles and constantly undergo fission and fusion to regulate their morphology, size and number. Mitochondrial dynamics are dependent on the metabolism regulation. Dysfunction of mitochondria fission/fusion can lead to the accumulation of abnormal mitochondria and contribute to cellular damage. Neurons consume the most energy, have a highly complex morphology, and are particularly dependent on mitochondrial function and thus damaged mitochondria may lead to neuronal death. Many **neurodegenerative diseases** such as Alzheimer's disease (AD), Parkinson's disease (PD), and multiple sclerosis (MS) are **associated with dysfunction of mitochondrial dynamics or metabolism**.

**SELECTED REVIEWS:** Mitochondrial Dynamics and Metabolic Regulation: T. Wai & T. Langer; Trends Endocrinol. Metab. 27, 105 (2016) · Metabolic regulation of mitochondrial dynamics: M. Prashant & D.C. Chan; J. Cell Biol. 212, 379 (2016)



**Ask for AdipoGen Life Sciences' Immunometabolism Brochure!**

## IDH1 – Biomarker and Target for Glioma and Glioblastoma

Isocitrate Dehydrogenase 1 (IDH1) is a soluble, cytosolic enzyme involved in the TCA metabolic cycle. The most notable mutation in this enzyme, R132H, is clinically indicated in the majority of astrocytomas and oligodendroglial tumors, with the mutation being associated with more favorable prognosis and increased survival in those patients. IDH1 R132H is also useful in the differential diagnosis between anaplastic glioma and glioblastoma.


### IHC GRADE IHC-Competent Antibody

#### NEW anti-IDH1 (R132H Mutant) (human), mAb

AG-20B-6024 100 µl | 1 ml

<b>Clone</b>	AG-IHC132
<b>Isotype</b>	Mouse IgG1
<b>Immunogen</b>	Synthetic IDH1 peptide
<b>Application</b>	IHC
<b>Specificity</b>	Recognizes human IDH1 mutated at R132H.

**FIGURE:** Immunohistochemical staining of mutated IDH1 (R132H) in formalin-fixed and paraffin-embedded (FFPE) human astrocytoma tissue.




### POTENT IDH1 (R132H) Inhibitor

#### AGI-5198

AG-CR1-3528 5 mg | 25 mg

<b>Formula</b>	C <sub>27</sub> H <sub>31</sub> FN <sub>4</sub> O <sub>2</sub>
<b>MW</b>	462.6
<b>CAS</b>	1355326-35-0

Potent and selective inhibitor of IDH1 (isocitrate dehydrogenase 1) R132H and R132C mutants *in vitro* with IC<sub>50</sub> values of 0.07 and 0.16 µM, respectively. Does not inhibit wild-type IDH1 or any of the examined IDH2 isoforms (IC<sub>50</sub> > 100 µM).



## UNIQUE


## Mitochondrial Pyruvate Carrier 2 (MPC-2) Monoclonal Antibody

#### NEW anti-MPC-2, mAb (JCM-1)

AG-20B-0071 100 µg

<b>Clone</b>	JCM-1
<b>Isotype</b>	Mouse IgG2bκ
<b>Application</b>	WB (1 µg/ml), IP (1:200), ICC (1:400)
<b>Specificity</b>	Recognizes endogenous human and mouse MPC-2.


**FIGURE:** Immunofluorescence analysis of HeLa cells overexpressing hMPC2-HA. Picture Courtesy of Sylvie Montessuit, Jean-Claude Martinou Lab, University of Geneva



# Netrin-1 – Neuron Guidance Factor Involved in iPS Regulation

**Netrin-1 is a guidance molecule** that triggers either attraction or repulsion effects on migrating axons of neurons, interacting with the receptors **DCC** or **UNC5** (A to D). It has been proposed that DCC and UNC5 are dependence receptors that, in the absence of netrin-1, promote apoptosis. This pro-apoptotic activity requires initial caspase cleavage of the receptor's intracellular domain. Netrin-1 is therefore a pro-survival factor acting by blocking cell death induced by its unbound receptors. Netrin-1 protects neurons from death during development and favors tumor epithelial cells survival in some types of cancers. It interacts with the orphan amyloid precursor protein (APP), a protein component of the amyloid plaques that are associated with Alzheimer's disease (AD). Netrin-1 also inhibits remyelination of neurons in Multiple Sclerosis (MS) (and other progressive demyelinating diseases) by inhibiting oligodendrocyte precursor migration. Recently, Netrin-1 has been described to be the **5th Element of classical iPS cell factors**. Netrin-1 functions in protecting embryonic stem cells from apoptosis and addition of recombinant Netrin-1 improves the generation of mouse and human iPS cells (induced Pluripotent Stem Cells).

**REVIEWS:** Netrin-1 in the developing enteric nervous system and colorectal cancer: S.Y. Ko, et al.; Trends Mol. Med. 18, 544 (2012) • Netrin-1 regulates somatic cell reprogramming and pluripotency maintenance: D. Ozmadenci, et al.; Nat. Commun. 6, ID7398 (2015)



Picture courtesy of Dr. Véronique Corset, Prof. Patrick Mehlen Lab, Centre Léon Bérard, Lyon

**FIGURE:** Netrin-1 (human):Fc (human) (rec.) (Prod. No. AG-40B-0075) induces outgrowth of the commissural axon.

**METHOD:** Dorsal spinal cords were dissected out from E13 rat embryos and cultured in collagen matrix in the presence or absence of netrin-1 (250ng/ml). Axons were then stained with an anti- $\beta$ -tubulin antibody.

## UNIQUE Biologically Active Human Netrin-1

PROTEINS	PID	SIZE	SOURCE	ENDOTOXIN	SPECIES
<b>Netrin-1 (human) (rec.)</b>	AG-40B-0040	10 $\mu$ g   3 x 10 $\mu$ g   100 $\mu$ g	HEK293 Cells	<0.01EU/ $\mu$ g	Hu, Ms, Rt
<b>Netrin-1 (human):Fc (human) (rec.)</b>	AG-40B-0075	10 $\mu$ g   3 x 10 $\mu$ g   100 $\mu$ g	HEK293 Cells	<0.1EU/ $\mu$ g	Hu, Ms, Rt
<b>UNC5B (human):Fc (human) (rec.)</b>	AG-40B-0037	50 $\mu$ g   3 x 50 $\mu$ g	HEK293 Cells	<0.1EU/ $\mu$ g	Hu, Ms

## NEW Potent Netrin-1 Blocking Antibody

ANTIBODY	PID	SIZE	ISOTYPE/SOURCE	APPLICATION	SPECIES
<b>anti-Netrin-1 (human), mAb (rec.) (blocking) (2F5) (preservative free)</b>	AG-27B-0018PF	100 $\mu$ g   500 $\mu$ g	Human IgG2	ELISA, FUNC	Hu, Ms

**LIT:** Epidermal Growth Factor Receptor-Dependent Mutual Amplification between Netrin-1 and the Hepatitis C Virus: M.L. Plissonnier, et al.; PLoS Biol. 14, e1002421 (2016) • Targeting netrin-1/DCC interaction in diffuse large B-cell and mantle cell lymphomas: T. Broutier, et al.; EMBO Mol. Med. 8, 96 (2016)

## LATEST INSIGHT

### Protective Role of Irisin in Alzheimer's Disease

Irisin is a protein cleaved from fibronectin type III domain-containing protein 5 (FNDC5) and has a beneficial role in adipose tissues, bone and brain. A recent study published in Nature Medicine by the labs of O. Arancio, S.Ferreira & F.G. de Felice (Rio de Janeiro, Brazil, New York, US and Kingston, Canada, respectively) showed that FNDC5/Irisin levels are reduced in Alzheimer's disease (AD) cerebrospinal fluid in human and mouse and that beneficial effects of exercise on synaptic plasticity and memory in AD models are mediated by FNDC5/Irisin. Addition of AdipoGen Life Sciences' recombinant Irisin (Prod. No. AG-40B-0136) in a mice model of AD was neuroprotective and rescued Amyloid- $\beta$  oligomer-induced memory impairment. AdipoGen Life Sciences provides the best recombinant Irisin/FNDC5 proteins, antibody and ELISA kit to study Irisin and FNDC5 *in vitro* and *in vivo*.

**LIT:** Exercise-linked FNDC5/irisin rescues synaptic plasticity and memory defects in Alzheimer's models: M.V. Lourenko, et al.; Nat. Med. 25, 165 (2019)

PROTEINS	PID
<b>Irisin (rec.) (CHO)</b>	AG-40B-0136
<b>Irisin:Fc (human) (rec.)</b>	AG-40B-0115
<b>Irisin (rec.) (untagged) (E.coli)</b>	AG-40B-0103
<b>FNDC5 (rec.) (untagged)</b>	AG-40B-0128
<b>FNDC5:Fc (human) (rec.)</b>	AG-40B-0153

PROTEINS	PID
<b>anti-Irisin, pAb (IN102)</b>	AG-25B-0027
<b>Irisin Competitive ELISA Kit</b>	AG-45A-0046Y

## Dyes & Stains for Neuron Labeling

PRODUCT NAME	PID	SIZE	DESCRIPTION
<b>N-(2-Aminoethyl)biotinamide . HCl</b>	CDX-A0191	50 mg   1 g	Used for neuronal tracing studies by visualizing neural architecture and for the identification of gap junction coupling.
<b>3,3'-Dipropylthiacarbocyanine iodide</b>	CDX-D0007	250 mg   500 mg	Carbocyanine dye used for detection of calcium channels and other ion transport systems, mitochondrial activity, and neurons and brain tissue.
<b>4-Di-2-ASP</b>	CDX-D0012	1 g   5 g	Cationic mitochondrial dye staining presynaptic nerve terminals independent of neuronal activity. Used to image neuronal cells in live animals.
<b>1,1'-Dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate</b>	CDX-D0230	100 mg   1 g	Endoplasmic reticulum membrane stain. Used as retrograde stain for neurons; provides intense, long-lasting staining of live neurons <i>in vivo</i> and <i>in vitro</i> .
<b>5,7-Dihydroxytryptamine . HBr</b>	CDX-H0026	10 mg   25 mg   250 mg	Autofluorescent serotonin derivative. Can be used for the identification of living serotonergic neurons even in the presence of dopaminergic neurons.
<b>Hydroxystilbamidine bis(methanesulfonate)</b>	CDX-H0100	10 mg	Hydroxystilbamidine (also called Fluoro Gold) is a cationic dye used for staining DNA and RNA and also frequently used as a retrograde neuronal tracer.
<b>Sulforhodamine 101</b>	CDX-S0025	100 mg   500 mg	Sulforhodamine 101 is a non-fixable red fluorescent dye used as a specific marker for astrocytes and an activity-dependent probe for monitoring regulated exocytosis. In addition to labeling astrocytes, it also labels myelinating oligodendrocytes.


## HDAC6 Inhibitors & Alzheimer's Disease

HDAC6 is one isoform of a family of HDAC enzymes that catalyze the removal of functional acetyl groups from proteins. It almost exclusively deacetylates cytoplasmic proteins. HDAC6 plays a pivotal role in the removal of misfolded proteins and is being investigated as target for lymphoid malignancies. Numerous recent studies have linked altered HDAC6 activity to the pathogenesis of neurodegenerative diseases that are characterized by misfolded protein accumulation.

**SELECTED REVIEWS:** The role of HDAC6 in Alzheimer's disease: L. Zhang, et al.; J. Alzheimers Dis. **33**, 283 (2013) • The therapeutic hope for HDAC6 inhibitors in malignancy and chronic disease: S.N. Batchu, et al.; Clin. Sci. **130**, 987 (2016) • HDAC6 as a potential therapeutic target for peripheral nerve disorders: R. Prior, et al.; Expert Opin. Ther. Targets **22**, 993 (2018)

PRODUCT NAME	PID	SIZE	HDAC6 INHIBITION	SELECTIVITY TOWARDS OTHER HDACS
<b>Tubastatin A [TubA]</b>	AG-CR1-3900	10 mg	IC <sub>50</sub> =15nM	Other HDACs (IC <sub>50</sub> = >15µM), HDAC8 (IC <sub>50</sub> =0.9µM)
<b>Nexturastat A</b>	AG-CR1-3901	1 mg   5 mg	IC <sub>50</sub> =5.02nM	Other HDACs (IC <sub>50</sub> =3-10µM)
<b>Nexturastat B</b>	AG-CR1-3902	1 mg   5 mg	IC <sub>50</sub> =3nM	HDAC1 (IC <sub>50</sub> =0.9µM)
<b>ACY-775</b>	AG-CR1-3903	1 mg   5 mg	IC <sub>50</sub> =7.5nM	HDAC1-9 (IC <sub>50</sub> =1-10µM)
<b>DMAPB</b>	AG-CR1-3904	1 mg   5 mg	IC <sub>50</sub> =114nM	Other HDACs (IC <sub>50</sub> =1-8µM)
<b>PMPH</b>	AG-CR1-3905	1 mg   5 mg	IC <sub>50</sub> =11nM	HDAC1 (IC <sub>50</sub> =1.5µM)
<b>DABPH</b>	AG-CR1-3906	1 mg   5 mg	IC <sub>50</sub> =12nM	HDAC1 (IC <sub>50</sub> =6.8µM)
<b>MBIMPH</b>	AG-CR1-3907	1 mg   5 mg	IC <sub>50</sub> =9nM	Other HDACs (IC <sub>50</sub> =0.1-12µM)
<b>MBIMPH F-Analog 1 . HCl</b>	AG-CR1-3908	1 mg   5 mg	IC <sub>50</sub> =3nM	Other HDACs (IC <sub>50</sub> =0.03-20µM)
<b>MBIMPH F-Analog 2</b>	AG-CR1-3909	1 mg   5 mg	IC <sub>50</sub> =5nM	Other HDACs (IC <sub>50</sub> =0.2-11 µM)
<b>MPI_5a</b>	SYN-3040	1 mg   5 mg   10 mg   50 mg   100 mg	IC <sub>50</sub> =36nM	Other HDACs (IC <sub>50</sub> =2-50µM)

**DYRK, Down Syndrome and MDR7**  
Please ask for our "DYRK Inhibitors" Product Flyer!




# Lead Compounds for Neurodegenerative Diseases

## Anti-Prion Agents – Protein Aggregation Inhibitors

### 6-Amino-8-trifluoromethylphenanthridine

AG-MR-C0031 1 mg | 5 mg | 25 mg

**Formula:** C<sub>14</sub>H<sub>9</sub>F<sub>3</sub>N<sub>2</sub>  
**MW:** 262.2  
**CAS:** 651055-83-3



### 6-Aminophenanthridine

AG-MR-C0029 1 mg | 5 mg | 25 mg

### Chloroguanabenz . acetate

AG-MR-C0036 1 mg | 5 mg

## Selective N- & P/Q-type Ca<sup>2+</sup>-Channel Agonist GV-58

AG-MR-C0035 1 mg | 5 mg

## Anti-Alzheimer's Disease (AD) Agent

### Leucettine L41

AG-MR-C0023 1 mg | 5 mg | 25 mg

## Alzheimer's Disease (AD) Accelerator

### Aftin-4

AG-MR-C0014 1 mg | 5 mg | 25 mg

### Aftin-5

AG-MR-C0015 1 mg | 5 mg | 25 mg

### Fipronil

AG-CR1-3648 100 mg | 1 g

## Potent and Selective $\gamma$ -Secretase Inhibitor

### Compound E

AG-CR1-0081 250  $\mu$ g | 1 mg | 5 mg

## Selected Agonists and Antagonists

PRODUCT NAME	ACTIVITY	PID	SIZE
<b>epi-Aszonalenin A</b>	Substance P inhibitor	AG-CN2-0163	1 mg   5 mg
<b>Bilobalide</b>	GABA(A) receptor antagonist	AG-CN2-0026	10 mg   50 mg
<b>Cyclopenin</b>	AChE inhibitor	AG-CN2-0134	1 mg   5 mg
<b>Debromohymenialdisine</b>	Potential anti-Alzheimer's agent	AG-CN2-0068	100 $\mu$ g
<b>EM574 [Motilide]</b>	Motilin receptor agonist	AG-CN2-0102	250 $\mu$ g   1 mg
<b>Flibanserin</b>	5-HT1A receptor agonist and 5-HT2A antagonist	CDX-F0337	5 mg   25 mg
<b>Fulvic acid</b>	Tau and A $\beta$ aggregation inhibitor	AG-CN2-0135	1 mg   5 mg
<b>Carbamoylcholine chloride</b>	Non-selective agonist nAChR and mAChR	AG-CR1-3649	100 mg   1 g
<b>Hyperforin . DCHA</b>	TRPC6 channel activator	AG-CN2-0008	500 $\mu$ g   1 mg
<b>20-Hydroxyecdysone</b>	GABA(A) receptor modulator	AG-CN2-0072	5 mg   10 mg   50 mg
<b>MTEP</b>	Potent mGluR5 antagonist	AG-CR1-0022	5 mg   25 mg
<b>NG 012</b>	NGF potentiator	AG-CN2-0155	1 mg   5 mg
<b>Pseurotin D</b>	Neuroleptic agent	BVT-0426	1 mg   5 mg
<b>Rotenone</b>	OXPPOS inhibitor used to induce Parkinson's diseases-like syndrome in experimental animal model	AG-CN2-0516	1 g   5 g
<b>Territrem B</b>	AChE inhibitor	AG-CN2-0142	500 $\mu$ g   1 mg
<b>Serratol</b>	TRPV3 activator	AG-CN2-0483	5 mg
<b>SNC80</b>	$\delta$ -Opioid receptor agonist	AG-CR1-0017	5 mg   25 mg
<b>Umbellulone</b>	Selective TRPA1 activator	AG-CN2-0085	10 mg
<b>URMC-099</b>	MLK-3 inhibitor for treatment of Parkinson's disease	SYN-1211	1 mg   5 mg   10 mg   50 mg   100 mg

Visit [www.adipogen.com](http://www.adipogen.com) for a Comprehensive Panel of Neurochemicals!